Yoshinobu Nakayama1, Nobuhiro Mukai1, Bing F Wang2, Kristen Yang1, Parth Patwari2, Richard N Kitsis3, Jun Yoshioka4. 1. Department of Molecular, Cellular & Biomedical Sciences, City University of New York School of Medicine, City College of New York, NY, New York, United States of America. 2. Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, United States of America. 3. Departments of Medicine and Cell Biology, Wilf Family Cardiovascular Research Institute, Albert Einstein College of Medicine, Bronx, NY, United States of America. 4. Department of Molecular, Cellular & Biomedical Sciences, City University of New York School of Medicine, City College of New York, NY, New York, United States of America; Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, United States of America. Electronic address: jyoshioka@med.cuny.edu.
Abstract
RATIONALE: Thioredoxin-interacting protein (Txnip) is a novel molecular target with translational potential in diverse human diseases. Txnip has several established cellular actions including binding to thioredoxin, a scavenger of reactive oxygen species (ROS). It has been long recognized from in vitro evidence that Txnip forms a disulfide bridge through cysteine 247 (C247) with reduced thioredoxin to inhibit the anti-oxidative properties of thioredoxin. However, the physiological significance of the Txnip-thioredoxin interaction remains largely undefined in vivo. OBJECTIVE: A single mutation of Txnip, C247S, abolishes the binding of Txnip with thioredoxin. Using a conditional and inducible approach with a mouse model of a mutant Txnip that does not bind thioredoxin, we tested whether the interaction of thioredoxin with Txnip is required for Txnip's pro-oxidative or cytotoxic effects in the heart. METHODS AND RESULTS: Overexpression of Txnip C247S in cells resulted in a reduction in ROS, due to an inability to inhibit thioredoxin. Hypoxia (1% O2, 24 h)-induced killing effects of Txnip were decreased by lower levels of cellular ROS in Txnip C247S-expressing cells compared with wild-type Txnip-expressing cells. Then, myocardial ischemic injuries were assessed in the animal model. Cardiomyocyte-specific Txnip C247S knock-in mice had better survival with smaller infarct size following myocardial infarction (MI) compared to control animals. The absence of Txnip's inhibition of thioredoxin promoted mitochondrial anti-oxidative capacities in cardiomyocytes, thereby protecting the heart from oxidative damage induced by MI. Furthermore, an unbiased RNA sequencing screen identified that hypoxia-inducible factor 1 signaling pathway was involved in Txnip C247S-mediated cardioprotective mechanisms. CONCLUSION: Txnip is a cysteine-containing redox protein that robustly regulates the thioredoxin system via a disulfide bond-switching mechanism in adult cardiomyocytes. Our results provide the direct in vivo evidence that regulation of redox state by Txnip is a crucial component for myocardial homeostasis under ischemic stress.
RATIONALE: Thioredoxin-interacting protein (Txnip) is a novel molecular target with translational potential in diverse human diseases. Txnip has several established cellular actions including binding to thioredoxin, a scavenger of reactive oxygen species (ROS). It has been long recognized from in vitro evidence that Txnip forms a disulfide bridge through cysteine 247 (C247) with reduced thioredoxin to inhibit the anti-oxidative properties of thioredoxin. However, the physiological significance of the Txnip-thioredoxin interaction remains largely undefined in vivo. OBJECTIVE: A single mutation of Txnip, C247S, abolishes the binding of Txnip with thioredoxin. Using a conditional and inducible approach with a mouse model of a mutant Txnip that does not bind thioredoxin, we tested whether the interaction of thioredoxin with Txnip is required for Txnip's pro-oxidative or cytotoxic effects in the heart. METHODS AND RESULTS: Overexpression of Txnip C247S in cells resulted in a reduction in ROS, due to an inability to inhibit thioredoxin. Hypoxia (1% O2, 24 h)-induced killing effects of Txnip were decreased by lower levels of cellular ROS in Txnip C247S-expressing cells compared with wild-type Txnip-expressing cells. Then, myocardial ischemic injuries were assessed in the animal model. Cardiomyocyte-specific Txnip C247S knock-in mice had better survival with smaller infarct size following myocardial infarction (MI) compared to control animals. The absence of Txnip's inhibition of thioredoxin promoted mitochondrial anti-oxidative capacities in cardiomyocytes, thereby protecting the heart from oxidative damage induced by MI. Furthermore, an unbiased RNA sequencing screen identified that hypoxia-inducible factor 1 signaling pathway was involved in Txnip C247S-mediated cardioprotective mechanisms. CONCLUSION: Txnip is a cysteine-containing redox protein that robustly regulates the thioredoxin system via a disulfide bond-switching mechanism in adult cardiomyocytes. Our results provide the direct in vivo evidence that regulation of redox state by Txnip is a crucial component for myocardial homeostasis under ischemic stress.
Authors: Jackie S Bodnar; Aurobindo Chatterjee; Lawrence W Castellani; David A Ross; Jeffrey Ohmen; James Cavalcoli; Chenyan Wu; Katherine M Dains; Joe Catanese; Michael Chu; Sonal S Sheth; Kanti Charugundla; Peter Demant; David B West; Pieter de Jong; Aldons J Lusis Journal: Nat Genet Date: 2001-12-20 Impact factor: 38.330
Authors: Guosheng Xiang; Tetsunori Seki; Michael D Schuster; Piotr Witkowski; Andrew J Boyle; Fiona See; Timothy P Martens; Alfred Kocher; Hugo Sondermeijer; Henry Krum; Silviu Itescu Journal: J Biol Chem Date: 2005-09-19 Impact factor: 5.157
Authors: Norimichi Koitabashi; Djahida Bedja; Ari L Zaiman; Yigal M Pinto; Manling Zhang; Kathleen L Gabrielson; Eiki Takimoto; David A Kass Journal: Circ Res Date: 2009-06-11 Impact factor: 17.367
Authors: Sang-Ging Ong; Won Hee Lee; Louise Theodorou; Kazuki Kodo; Shiang Y Lim; Deepa H Shukla; Thomas Briston; Serafim Kiriakidis; Margaret Ashcroft; Sean M Davidson; Patrick H Maxwell; Derek M Yellon; Derek J Hausenloy Journal: Cardiovasc Res Date: 2014-07-25 Impact factor: 10.787